埋もれた研究成果の意図せざる引継ぎ : 高血圧症治療薬のR&Dプロセスの事例研究
スポンサーリンク
概要
- 論文の詳細を見る
This paper explores how and why an innovation, which originated with a failure of a certain company's R & D to deliver a successful breakthrough product, had been created through a research outcome transfer between companies without any collaborative alliance. Recent years, many literatures have discussed the "Open Innovation" which creates value by organically integrating outside ideas into inside firms. Traditional innovation was created through such a closed cycle that investing in corporate R & D for new technology and increasing the sales and profit would render continuous R & D investment to the firm. Many companies, however, have found traditional innovation unsustainable due to the change of environment around market and R & D. Then, one question is if some breakthrough product is invented and developed through open innovation, does it necessarily require any collaborative relationship? Under such a research question, a successful case of R & D for hypertension drug was picked up to investigate the process and the mechanism of open innovation at Takeda Pharmaceutical Company. As a result, the firm had once found a brand-new and potential basic skeleton of chemical compound, but failed in a productization. Before that, Takeda had already filed the patent application and an overseas chemical company DuPont referred to the registered patent when it was open. Not knowing the Takeda's failure, DuPont had attempted to develop the chemical compound to squeeze through the problem due to some experience and knowledge about the mechanism of the research outcome. A few years later, DuPont made a presentation at an international conference, allowing Takeda to know their invention. Takeda had immediately restarted the project to find better chemical compound. Although another 60 companies all over the world also joined this competition, Takeda successfully found better one due to the abundant experience. Now, the sales of the product have marked the top position in the Japanese medicine market for all diseases.
- 2008-04-20